Seth Fischer
Director/Board Member bij AGILE THERAPEUTICS, INC.
Vermogen: 68 609 $ op 31-03-2024
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
John Johnson | M | 66 |
Ortho-McNeil Pharmaceutical LLC
Ortho-McNeil Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Ortho-McNeil Pharmaceutical LLC manufactures pharmaceutical products. Its products include ditropan, elmiron, modicon, otho cept and ortho novum etc. The company was founded in 1993 and is headquartered in Raritan, NJ.
Healthquest Capital Management Co LLC
Healthquest Capital Management Co LLC Investment ManagersFinance HealthQuest Capital Management Co LLC (HealthQuest Capital ) is a private equity firm founded in 2013 by Garheng Kong. The firm is headquartered in Redwood City, California. | 21 jaar |
Scott Coiante | M | 57 | 11 jaar | |
Nicole Vitullo | F | 66 | 19 jaar | |
Scott Braunstein | M | 60 | 6 jaar | |
Al Altomari | M | 65 | 20 jaar | |
Joaquin Duato | M | 61 | 35 jaar | |
J. Carroll | M | 74 | 4 jaar | |
Robert Wills | M | 70 | 31 jaar | |
Sheldon Koenig | M | 58 | 4 jaar | |
Geoffrey P. Gilmore | M | 58 | 10 jaar | |
Steven Pfanstiel | M | 51 | 3 jaar | |
Michael Tomsicek | M | 58 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 jaar |
Matthew Riley | M | - | 4 jaar | |
Nora Brennan | F | 55 | 4 jaar | |
Joseph Oliveto | M | 56 | 7 jaar | |
William Hait | M | 74 | 17 jaar | |
Marianne Andreach | F | - | - | |
Josephine Torrente | F | 58 | 3 jaar | |
Joseph Wolk | M | 57 | 26 jaar | |
Kimberly Whelan | F | - | 5 jaar | |
Christine Silverstein | F | 41 | 1 jaar | |
Benjamin Halladay | M | 38 | 4 jaar | |
Sharon Barbari | F | 70 | 4 jaar | |
Charles Austin | M | 68 | 4 jaar | |
Amy Welsh | F | 53 | 4 jaar | |
Avery Williams | F | - |
Healthquest Capital Management Co LLC
Healthquest Capital Management Co LLC Investment ManagersFinance HealthQuest Capital Management Co LLC (HealthQuest Capital ) is a private equity firm founded in 2013 by Garheng Kong. The firm is headquartered in Redwood City, California. | 2 jaar |
Benjamin Looker | M | 42 | 2 jaar | |
Lisa Giles | F | 65 | 4 jaar | |
David Kabakoff | M | 76 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA.
Healthquest Capital Management Co LLC
Healthquest Capital Management Co LLC Investment ManagersFinance HealthQuest Capital Management Co LLC (HealthQuest Capital ) is a private equity firm founded in 2013 by Garheng Kong. The firm is headquartered in Redwood City, California. | 18 jaar |
Sandra A. Carson | M | 70 | 4 jaar | |
Richard Pasternak | M | 75 | 5 jaar | |
David King | M | 67 |
Healthquest Capital Management Co LLC
Healthquest Capital Management Co LLC Investment ManagersFinance HealthQuest Capital Management Co LLC (HealthQuest Capital ) is a private equity firm founded in 2013 by Garheng Kong. The firm is headquartered in Redwood City, California. | 11 jaar |
Alan Fuhrman | M | 67 | 4 jaar | |
Anne Mulcahy | F | 70 | 15 jaar | |
Antonio M. Gotto | M | 88 | 10 jaar | |
Jay Shepard | M | 66 | 6 jaar | |
Tim Mayleben | M | 63 | 16 jaar | |
Martha Manning | F | 69 | 4 jaar | |
Eric Warren | M | 76 | 3 jaar | |
Elan Ezickson | M | 60 | 5 jaar | |
Garheng Kong | M | 49 |
Healthquest Capital Management Co LLC
Healthquest Capital Management Co LLC Investment ManagersFinance HealthQuest Capital Management Co LLC (HealthQuest Capital ) is a private equity firm founded in 2013 by Garheng Kong. The firm is headquartered in Redwood City, California. | 12 jaar |
Tracy M. Woody | F | 54 | 5 jaar | |
John Hubbard | M | 67 | 10 jaar | |
Debra Liebert | F | 67 | 9 jaar | |
Robert Conway | M | 67 | 20 jaar | |
Sara Nochur | M | 63 | 3 jaar | |
Peter Fasolo | M | 61 | 18 jaar | |
Stephen Rocamboli | M | 52 | 2 jaar | |
Ajay Madan | M | - |
Healthquest Capital Management Co LLC
Healthquest Capital Management Co LLC Investment ManagersFinance HealthQuest Capital Management Co LLC (HealthQuest Capital ) is a private equity firm founded in 2013 by Garheng Kong. The firm is headquartered in Redwood City, California. | 1 jaar |
Sonya Weigle | F | - | 3 jaar | |
Paul Korner | M | 58 | 4 jaar | |
Marvin Johnson | M | 61 | 1 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Thomas Riga | M | 48 | 10 jaar | |
Joseph W. Turgeon | M | 66 | 9 jaar | |
Timothy Morris | M | 61 | 9 jaar | |
Alex Gorsky | M | 63 | 35 jaar | |
Robert Wilson | M | 83 | 41 jaar | |
Christopher Michael Cashman | M | 67 | 8 jaar | |
Jeffrey O'Donnell | M | 64 | 10 jaar | |
Edward Smith | M | 53 | 8 jaar | |
Thomas King | M | 69 | 3 jaar | |
Russell C. Deyo | M | 74 | 27 jaar | |
Mark B. Logan | M | 84 | 15 jaar | |
Jeffrey Stein | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 jaar |
Ajit Shetty | M | 77 | 13 jaar | |
John Schmid | M | 60 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 9 jaar |
Peter Y. Tam | M | 60 | 20 jaar | |
Michael H. Ullmann | M | 66 | 33 jaar | |
Kurt Gustafson | M | 56 | 9 jaar | |
Mark Oki | M | 55 | - | |
Joseph Scodari | M | 71 | 9 jaar | |
Greg Cash | M | 66 | 3 jaar | |
Michael Astrue | M | 67 | 1 jaar | |
Matthew Stuckley | M | - | 14 jaar | |
James T. Lenehan | M | 75 | 28 jaar | |
Roy Tanaka | M | 75 |
Biosense Webster, Inc.
Biosense Webster, Inc. Medical SpecialtiesHealth Technology Biosense Webster, Inc. develops technology solutions for diagnosing heart rhythm disorders. It provides deflectable tip catheter for treating arrhythmia disorder. The company was founded by Wilton W. Webster Jr. and Shlomo Ben-Haim in 1998 and is headquartered in South Diamond Bar, CA. | 19 jaar |
Rick Bartram | M | 63 | 9 jaar | |
Kalyanam Shivkumar | M | 56 | 2 jaar | |
Enrique Carrazana | M | 62 | 8 jaar | |
Sasha Ellis | F | - | - | |
Andrew Filler | M | 56 | 4 jaar | |
Tiffini Wittwer | F | - | - | |
Tracy Guo | F | - | - | |
Donald Foley | M | 73 | 9 jaar | |
Patrick Gallagher | M | 59 | 10 jaar | |
Jerome Zeldis | M | 74 | 1 jaar | |
Lisa M. Caperelli | F | - | 6 jaar | |
Anand Mehra | M | 48 | 9 jaar | |
Paul Truex | M | 55 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 5 jaar |
Theodore Schroeder | M | 69 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 4 jaar |
Brendan M. O'Leary | M | 52 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 3 jaar |
Abhijeet Lele | M | 58 | 10 jaar | |
David Weild | M | 67 | 9 jaar | |
William McKee | M | 62 | 6 jaar | |
Karen Ho Hong | M | 52 | 10 jaar | |
Brian Atwood | M | 71 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | 6 jaar |
Dominic Caruso | M | 66 |
Ortho-McNeil Pharmaceutical LLC
Ortho-McNeil Pharmaceutical LLC Pharmaceuticals: MajorHealth Technology Ortho-McNeil Pharmaceutical LLC manufactures pharmaceutical products. Its products include ditropan, elmiron, modicon, otho cept and ortho novum etc. The company was founded in 1993 and is headquartered in Raritan, NJ. | 19 jaar |
Matthew W. Onaitis | M | 53 |
Trius Therapeutics, Inc.
Trius Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Trius Therapeutics, Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. It engages in developing tedizolid phosphate an intravenous, or IV, and oral antibiotic, for the treatment of serious gram-positive bacterial infections, initially for acute bacterial skin and skin structure infections, ABSSSI, and subsequently for other indications, including pneumonia. ABSSSI is a new classification for complicated skin and skin structure infections, or cSSSI. Tedizolid phosphate is an IV and orally administered second generation oxazolidinone. The company develops antibiotics for gram-negative infections. Trius Therapeutics was founded by John Finn and John P. Schmid in June 2004, and is headquartered in San Diego, CA. | - |
Jason Butch | M | 47 | 3 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 95 | 95.96% |
Canada | 6 | 6.06% |
België | 1 | 1.01% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Seth Fischer
- Persoonlijk netwerk